DLC1 (deleted in liver cancer 1), a tumor suppressor gene that encodes a RhoGTPase-activating protein, is recurrently downregulated or silenced in various solid tumors and hematological malignancies because of epigenetic modifications or genomic deletion. Here, we identified DLC1 promoter hypermethylation in 43 out of 44 multiple myeloma (MM) cell lines, which resulted in downregulation or silencing of DLC1 in 41 samples. High frequency of tumor-specific methylation and attenuation or silencing of DLC1 expression could serve as an independent diagnostic marker for MM. Combined treatment with demethylating and acetylating agents significantly elevated the expression of DLC1 and suppressed MM cell proliferation. Two cell lines exhibiting complete promoter methylation and the absence of DLC1 expression were transduced by an adenoviral vector containing DLC1 cDNA. In both cell lines, the reexpression of DLC1 inhibited myeloma cell invasion and migration, reduced RhoA activity and resulted in the reorganization of actin cytoskeleton. These results provide the first evidence for the antiproliferative effect of DLC1 in a hematological cancer and implicate RhoA pathway in suppression of MM migration and invasion. Given the myeloma cells sensitivity to the reactivation of DLC1 function, the potential for molecular targeted therapy of DLC1-mediated pathways as well as epigenetic therapies hold prospects.
Introduction
Multiple myeloma (MM), a malignant B-cell tumor, is the second most frequent hematological cancer, with an estimated 16 000 new cases each year in the United States. The incidence of MM is two-fold higher in African-American descendents than in Caucasians and affects men more frequently than women. [1] [2] [3] The disease occurs de novo or evolves from benign monoclonal gammopathy. Clinical manifestations of MM because of the accumulation of plasma cells in the bone marrow and excessive levels of monoclonal immunoglobulin can result in osteolytic lesions, anemia, myelosuppression and renal dysfunction. Ionizing radiation and certain environmental chemicals have been linked to the development of MM, whereas rare familial cases are suggestive of a genetic susceptibility component. [4] [5] [6] Despite significant efforts, the therapy of MM is unsatisfactory and only a fraction of patients survive longer than 10 years after diagnosis. The poor response to therapy could be at least partially attributed to the heterogeneity of the disease that is characterized by cell populations with numerous structural and numerical chromosomal alterations. 7 Rapid advancements in array technologies for genome-wide screening of changes in gene expression and DNA copy number have raised the prospects for a better understanding of the pathogenesis of MM, improvements in early detection, new prognostic classification and the identification of new therapeutic targets. 2 A recent comprehensive and integrated array-comparative genomic hybridization analysis illustrates the potential benefits of this approach. This analysis uncovered distinct genomic subtypes of MM and defined 87 discrete minimal regions of recurrent amplification and deletion that harbor known or still unknown oncogenes and tumor suppressor genes that may be implicated in pathogenesis of MM. 6 One of the recurrently deleted region in MM is 8p23.3-8p21.3, which contains deleted in liver cancer 1 (DLC1) gene encoding a RhoGTPase-activating protein (RhoGAP). 6, 8 In several major types of cancer, the reintroduction of DLC1 into tumor cells lacking expression of the endogenous gene suppresses tumor cell proliferation, migration and invasion; induces apoptosis in vitro and reduces or prevents the formation of tumors and metastases in nude mice, 9 and a recent study using shRNAmediated knockdown of DLC1 expression in a mouse liver tumor model confirmed that DLC1 is a bona fide tumor suppressor gene. 10 Mutations in the coding region of DLC1 are rare in human cancers, whereas homozygous or heterozygous deletion of DLC1 was detected in several solid tumors. In liver, lung, colon and breast tumors, the incidence of heterozygous DLC1 deletions is higher than that of the INK4/ARF, PTEN or p53 tumor suppressor genes. 10 Epigenetic mechanisms are, however, predominantly responsible for downregulation and silencing of DLC1 in human cancers, and particularly in hematological malignancies. 9 Although DLC1 is not methylated in normal bone marrow and lymphocytes, DLC1 promoter hypermethylation has been detected in over 80% of patients with acute lymphoblastic leukemia and non-Hodgkin's lymphoma. [11] [12] [13] [14] As in other hematological malignancies, DLC1 was found hypermethylated in 78% of patients with MM and in six out of nine MM cell lines. 15, 16 In Drosophila, RhoGTPases are downstream mediators of the Wnt signaling pathway. There is conclusive evidence that the two signaling pathways are interconnected in mammalian cells, and that both are frequently activated in certain cancers. 17, 18 It has been shown that Wnt-mediated migration of MM cells requires the activation of RhoAGTPase and some of protein kinase C family members.
19 DLC1 is a RhoGAP specific for RhoA, and may thus play a role in myeloma cell migration and invasion.
Given the well-documented antitumor effect of DLC1 in various solid neoplasms and the lack of any information regarding the mechanism of its oncosuppressive activity in hematological malignancies, we decided to examine the involvement of DLC1 in MM. Thus, we screened 44 MM cell lines for abnormal DLC1 promoter methylation and mRNA expression, and found that the majority of the cell lines exhibited various degree of promoter hypermethylation that correlated with downregulation or silencing of DLC1 expression. Treatment of two cell lines lacking DLC1 expression because of full promoter hypermethylation with demethylating and acetylating agents significantly augmented the expression of DLC1 and inhibited cell proliferation. Transfer of DLC1 cDNA to these cell lines by an adenoviral vector that was earlier successfully used for expressing DLC1 in prostate and hepatocellular carcinoma cells 20, 21 resulted in the suppression of cell migration and invasion, associated with a significant reduction of RhoA activity and in changes in the amount and distribution of actin content. These observations provide the first evidence for the oncosuppressive function of DLC1 in a hematological cancer and raise the possibility of therapeutic intervention in MM.
Materials and methods

Methylation-specific PCR
Genomic DNA extracted from MM cell lines modified by sodium bisulfite using the EZ DNA Methylation Kit (ZYMO Research, Orange, CA, USA) according to the manufacturer's instructions. For detection of aberrant methylation of the DLC1 gene, modified DNA was amplified either using primers (MSP-F, MSP-R) specific for the methylated sequences 22 or primers (USP-F, USP-R) specific for the unmethylated sequence of this gene. Hot-started PCR was performed in a 50 ml reaction volume using HotstarTaq DNA Polymerase (Qiagen, Valencia, CA, USA) (conditions at 95 1C, at 94 1C for 30 s, at 58 1C for 30 s, at 72 1C for 30 s for 35 cycles, at 72 1C for 10 min. A volume of 8 ml of the products was run on a 2% agarose gel and visualized under ultraviolet illumination.
Plasma cell enrichment and flow cytometry
Plasma cell enrichment was performed as described earlier, 23 and B cells were enriched from buffy coat of healthy donors by using StemSep B-cell purification antibody mixtures (StemCell Technologies, Vancouver, BC, Canada). Purified B cells were stained with various monoclonal antibody combinations for 20 min on ice in staining buffer (1% bovine serum albumin and 5% fetal calf serum in phosphate-buffered saline). The directly conjugated monoclonal antibodies used were anti-CD27-PE, anti-CD19-PerCpCy5.5 and anti-CD38-allophycocyanin (clone HB7; BD Immunocytometry, San Jose, CA, USA). Stained cells were washed and data were collected immediately using a fourcolor FACSCalibur (BD Biosciences, Franklin Lakes, NJ, USA). Data were analyzed using FlowJo software (Tree Star). B-cell populations were sorted using the Dako Cytomation MoFlo (498% pure). The plasma cell population, on the basis of phenotype (CD19low, CD27high and CD38high), was isolated from the B-cell population for further analysis.
Sodium bisulfite DNA sequencing
Genomic DNA extracted from MM cell lines with either full or heavy methylation was modified by sodium bisulfite using EZ DNA Methylation Kit (ZYMO Research) according to the manufacturer's instructions. The bisulfite-modified DNA was amplified by PCR using the specific primers (BIS-DLC-F, BIS-DLC-R). PCR products were then subcloned into the pCR2.1-TOPO vector using a TA cloning kit (Invitrogen Carlsbad, CA, USA). To determine the CpG methylation status of the 5 0 CpG island of DLC1 gene, four clones from each plate were sequenced using an ABI PRISM Dye Deoxyterminator Cycle Sequencing Kit and analyzed on an ABI 377 DNA Sequencer (Applied Biosystems, Foster City, CA, USA).
Cell culture
Human MM cell lines U266, Delta47 and OPM2 were kindly provided by Janet Pumphrey (National Cancer Institute, Bethesda, MD, USA). The human bone marrow stromal cell line HS-5 was purchased from the American Type Culture Collection (Manassas, VA, USA). All the cell lines were maintained in RPMI 1640 media supplemented with 10% fetal bovine serum and antibiotics (Biosource, Camarillo, CA, USA) in 5% CO 2 and 37 1C. 
Quantitative and semiquantitative RT-PCR
Total RNA isolation and quantitative real-time reverse transcriptase-PCR (RT-PCR) of DLC1 and GAPDH (glyceraldehyde 3-phosphate dehydrogenase) were described earlier. 22 To evaluate differences in DLC1 expression between the samples, the normal bone marrow cell value was used as a calibrator, its expression of DLC1 was set as 1, and the difference from DLC1 expression in myeloma cell lines was revealed by the 2 ÀDDCt method. Significant difference was considered when 2 ÀDDCt was X2. Semiquantitative RT-PCR was performed using PCR Supermix (Invitrogen) and primers DLC1 7F and DLC1 9R for amplification of DLC1. Samples were considered positive when a DLC1 PCR product was detected after 30 cycles of amplification. GAPDH was used as an internal control of amplification, and PCR was carried out using primers GAPDH R and GAPDH L (Table 1) .
Cell proliferation assay
To determine the effects of 5-aza-dC and TSA and their combination on cell growth, 10 4 5-aza-dC and TSA-treated 
Cell transfection
Myeloma cell lines at a density of 10 6 cells in 3 ml total volume (six-well plate) were transfected with an adenovirus vector pAd/ CMV/V5-GW containing cDNA encoding the open reading frame of DLC1 or LacZ for 72 h according to the manufacturer's protocol (Invitrogen). Efficiency of adenovirus transfection of LacZ was checked by the b-Galactosidase Staining Kit (Invitrogen) according to the manufacturer's protocol. Transfected cells were fixed with fixative solution and then stained for 4 h in 37 1C. Blue-colored cells were counted under a microscope. The reexpression of DLC1 was checked by real-time RT-PCR.
Transendothelial migration and invasion assay
Transendothelial migration of MM cell lines U266 and delta47 was performed as described earlier. 24 Human recombinant insulin-like growth factor-1 (IGF-1) at concentration of 50 ng/ml was added to the lower chamber as a decoy chemoattractant. Matrigel invasion chambers (BD Bioscience, Bedford, MA, USA) were seeded with 5 Â 10 4 cells per well and incubated overnight in 37 1C, and 50 ng/ml IGF-1 was added into lower chamber as a decoy chemoattractant. At the end of incubation period, inserts were cleaned from Matrigel, fixed in 75% ethanol for 5 min and stained by 0.05% crystal violet for 2 min according to the manufacturer's protocol. Invading cells were counted under microscope. All migration and invasion experiments were performed in triplicates.
RhoA activation assay
The relative RhoA activity in two MM cell lines, Delta47 and U266, was measured by using an ELISA-based RhoA activation assay kit (G-LISA, Cytoskeleton Inc. Denver, CO, USA), according to the manufacturer's instructions. The cells were transduced with Ad-DLC1 and Ad-LacZ for 72 h. After serum starvation and lysophosphatidic acid stimulation, cells were lysed and the protein concentrations were determined according to the manufacturer's protocol. The lysates were incubated in microwells coated with the Rhotekin Rho-binding domain, and the levels of active RhoA were measured using indirect immunodetection followed by a colorimetric reaction measured by absorbance at 490 nm.
Fluorescence microscopy analysis
For detection of F-actin, MM cells were cultured as described and centrifuged onto precleaned microscopic slides using CytoSystem attachments in a Heraeus Megafuge 1R centrifuge, at 800 or 1200 r.p.m. for 5 min. Slides were fixed in paraformaldehyde, inspected under phase-contrast microscope and stained with rhodamine-phalloidin according to earlier published protocol. 25 Multiple sequential grayscale images were recorded using Photometrics Cold Snap HQ CCD camera mounted on Zeiss Axiophot microscope equipped with motorized shutter and filter wheel, and controlled by Apple Macintosh computer trough IP Lab Spectrum software.
Results and discussion
Aberrant DLC1 promoter methylation and mRNA expression
Given the high frequency of DLC1 expression downregulation or inactivation mediated by epigenetic mechanisms in various hematological malignancies, including patients with MM, we examined the DLC1 promoter methylation status and mRNA expression in 44 MM cell lines, and in samples of plasma cells derived from normal donors. As expected, we found no signs of DLC1 promoter methylation in normal plasma cells from healthy donors and in only one of the MM cell lines, that is H929 (Figure 1) . The remaining cells lines exhibited different degrees of abnormal methylation, ranging from light to full ( Table 2 ). The methylation patterns of the 35 CpG sites in the promoter region of the DLC1 gene were determined by bisulfite genomic DNA sequencing. To see the effect of aberrant promoter methylation on DLC1 mRNA expression, RNA from the 44 MM cell lines and from samples of plasma cells derived from normal donors was screened by real-time PCR (Figure 2 ) and conventional RT-PCR. Only three cell lines expressed DLC1 at levels comparable with those in normal plasma cells, whereas in the remaining lines downregulation or loss of DLC1 expression was found ( Table 2) .
Gene silencing by aberrant promoter methylation or by histone deacetylation in various types of human cancers has been reported at least as frequently as inactivation by the means of mutation or deletion. 26, 27 Molecular studies of MM so far have largely addressed the role of genetic abnormalities acquired through specific chromosome rearrangements, whereas they focused considerably less on the impact of epigenetic modifications, a major mechanism associated with loss of tumor suppressor gene function. 28 The high frequency of abnormal, tumor-specific, methylation of DLC1 promoter observed in this series of MM cell lines, as well as in patients with MM, 15 exceeds the rate of epigenetic silencing of several other tumor suppressor genes known to be involved in pathogenesis of this cancer. 28 It, therefore, may provide a useful independent marker for diagnosis of this neoplasm. More important, however, would be to establish a correlation between DLC1 methylation pattern and clinical characteristics in a large cohort of MM patients, as it was done in the case of p16 gene, where abnormal methylation at diagnosis was associated with unfavorable prognosis. 28 
Restoration of DLC1 expression by 5-aza-dC and TSA treatment
Although promoter methylation is the predominant mechanism of epigenetic DLC1 silencing, histone deacetylation is also an important component in this process, as demonstrated in Figure 1 Methylation-specific PCR detection of bisulfite-modified and amplified unmethylated (U) and methylated (M) sequences of DLC1 gene in two normal plasma cell samples (N1, N2) and six multiple myeloma cell lines shows different levels of DLC1 promoter methylation from none (N1, N2 and H929) to moderate (KMM1 and KHM11) to total methylation (U266, Delta47 and ANBL6).
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experiments with DNA samples from patients and cell lines derived from MM and prostate carcinoma. 15, 22 Furthermore, optimal reexpression of epigenetically silenced genes in myelodysplastic syndrome or acute myeloid leukemia was achieved, both in vitro and in vivo, when application of DNA methyltransferase inhibitors was sequentially followed by histone deacetylase inhibitors. 29 Given this proven approach, MM cell lines U266 and Delta47, that lacked intrinsic DLC1 expression, were treated with 5-aza-dC, TSA or by combination of both drugs.
Although treatment with 5-aza-dC was able to restore DLC1 expression in Delta47 cells, that effect in U266 was negligible. Only combined treatment with 5-aza-dC and TSA significantly restored the expression of DLC1 in both cell lines (Figures 3a  and b) , although the response was again more pronounced in the case of Delta47 cells. The response to treatment was equally dose-and time-dependent. Longer treatment (96 h) with higher dose of 5-aza-dC (5 mM) invariably produced a stronger response. The 5-aza-dC-and TSA-mediated induction of DLC1 mRNA were paralleled by a decrease in cell proliferation (Figures 3c and d) . Again, the effect in Delta47 cells was stronger than in U266, whereas the dynamics of growth inhibition followed partially only the dose-and/or timedependent pattern. These results have significant therapeutic implications in MM, as downregulation or silencing of tumor suppressor genes by promoter methylation and histone deacetylation makes them an attractive target for epigenetic therapy with DNA methylation inhibitors and histone deacetylase inhibitors. A powerful single or combinatorial protocol would consist of treatment with zebularine, a stable DNA cytosine DNA methylation inhibitor that preferentially targets cancer cells, and suberoylanilide hydroxamic acid (SAHA), a potent histone deacetylase inhibitor already tested in clinical trials for advanced leukemia and myelodysplastic syndromes. 30, 31 This potential therapeutic approach was recently highlighted in a remarkable article outlining several therapeutic options in tumors with disabled DLC1.
32
Adenovirus-mediated restoration of DLC1 expression and its effect on MM cell migration and invasion
To address the role of DLC1 on the capacity of MM cells to migrate and invade, we first examined Delta47 and U266 cells by RT-PCR and real-time RT-PCR analysis after adenovirusmediated DLC1 transduction. In both cell lines, we found a robust increase in DLC1 expression in DLC1-transduced cell as compared with controls (Figures 4a and b) . Then we used a transwell migration assay and matrigel invasion assay to measure the ability of MM cells transfected with DLC1 or the LacZ control to penetrate the layer of stromal bone morrow cells. In both cell lines, the DLC1-positive cells showed significantly a lower rate of migration (Figure 4c ) than those transfected by LacZ. DLC1 expression reduced migration of Delta47 and U266 cells by 39 and 20%, respectively. Experiments using Matrigel-coated invasion chambers revealed that the reexpression of DLC1 was considerably more effective in inhibiting MM cell invasion. AdDLC1 transduction of Delta47 and U266 cells resulted in the reduction of cell invasion of 53 and 48%, respectively, as compared with LacZ control samples (Figure 4d ). DLC1-mediated suppression of cell migration and invasion are of significant importance, as the two processes are instrumental in the myeloma cell movement within the bone marrow and metastasis to secondary sites. 19 Existing evidence suggests that DLC1 meets the criteria of a metastasis suppressor gene, 33 as restoration of DCL1 inhibited the dissemination of human hepatocellular carcinoma and breast cancer cells to distant organs in nude mice. 21, 34 DLC1 effect on RhoA activity and cytoskeleton organization Given the findings that DLC1-mediated inhibition of liver, lung or prostate tumor cell growth is associated with the suppression of RhoA activity, and evidence that the Rho pathway may play a role in malignant cell invasion in MM, we sought to see whether the restoration of DLC1 function was accompanied with a reduction of RhoA activity. The levels of active, GTP-bound RhoA ( Figure 5 ) in DLC1-transduced Delta47 and U266 cells were 60-70% lower, respectively, than in LacZ-transduced cells (P ¼ 0.037). Since the identification of the small GTPase, the first human oncogene, there has been a sustained interest in whether Abbreviation: DLC1, deleted in liver cancer 1.
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RhoGTPase-like ras contribute to cell transformation and tumor progression. 35, 36 Rho-GTPase activity is frequently deregulated in human cancers, and experimental evidence has implicated Rho-GTPase signaling in promoting the growth and invasiveness of tumor cells. [36] [37] [38] In the past several years, it became evident that the loss of DLC1 expression is one of the most frequent mechanism for the aberrant activation of Rho GTPases in human oncogenesis. DLC1-mediated negative regulatory effect of cell growth and tumorigenicity is primarily because of RhoGAP ability to inactivate Rho proteins, and several groups found that DLC1 is a potent GTPase-activating protein for RhoA. 20, [39] [40] [41] Although the suppressive effect of ectopic restoration of DLC1 expression on the ability of human cancer cell lines to form primary tumors and metastases was demonstrated by several independent groups, 9 the role of the loss of DLC1 in promoting neoplasia was recently demonstrated in a landmark study using Gene expression was normalized to the expression of control gene GAPDH. Normal bone marrow was used as a calibrator, its expression of DLC1 was set at 1, and the difference from DLC1 expression in myeloma cell lines was revealed by the 2 ÀDDCt method. Samples were divided into three subgroups according to the level of expressed DLC1 mRNA, and median of expression was determined for each subgroup.
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10 DLC1 knock down cooperated with c-myc overexpression to induce hepatocellular carcinomas in mice. 10 The loss of DLC1 conferred dependency on the RhoA pathway, as suppression of RhoA inhibited the growth of DLC1-negative hepatoma cells. 10 Such events are recapitulated in the pathogenesis of MM. Amplification or complex chromosomal translocations deregulate myc gene during the progression of MM, and as shown here the reintroduction of DLC1 decreased RhoA activity and suppressed myeloma cells migration and invasion.
2,7,42
RhoA can be activated in response to B-cell receptor signaling and regulates B-cell receptor-dependent cell proliferation. 43 Conceivably, ectopic restoration of DLC1 expression may interfere with B-cell receptor signaling, resulting in the reduction of RhoA activity and the inhibition of myeloma cell proliferation.
As Rho proteins play an important role in the control of actin cytoskeleton organization and focal adhesion assembly, we examined the effect of DLC1 expression on cytoskeletal organization in MM cells. 44, 45 DLC1-negative Delta47 cells showed a dense web of F-actin with the strong presence on the cell periphery and cytoplasmic protrusions, and detectable fibers throughout the cytoplasm ( Figure 6 , top panel). Cells in which DLC1 expression was restored by adenoviral transduction ( Figure 6, bottom panel) showed an overall reduction in F-actin, with sporadic accumulations on the perimeter, and almost no intracytoplasmic fibers. Although relatively little data are available on the characteristics of the MM cell cytoskeleton, our results appear to be consistent with observations that the amount of detectable F-actin and its intracellular distribution in MM cells fluctuates relative to cell motility; 46 motile cells show an increased overall density of F-actin in both the cortical band and the cytoplasm in contrast to immotile cells, which contain fewer actin filaments, localized almost exclusively to the cell perimeter.
Treatment of MM cells with Wnt or IGF-1 has been shown to cause rearrangements of the actin that are associated with the activation of RhoA. 19, 24, 47 The levels of F-actin and changes in its intracellular distribution in DLC1-transduced MM cells seem to be a consequence of the DLC1-mediated reduction of RhoA activity, and it is consistent with observations on cytoskeleton changes in DLC1-transduced prostate, liver and lung tumor cells. 21, 39, 48 It has been shown that the Wnt-mediated migration In conclusion, our results show for the first time that DLC1 has oncosuppressive activity in a hematological cancer. Signaling pathways modulated by DLC1 may have wide therapeutic applications. 10, 32, 49 Current observations show that DLC1 suppression of myeloma cell motility involves RhoA pathway that should be considered as one of the potential molecular targets for therapeutic interventions. 
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